5-Methylthiobenzothiophen | 51846-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-Methylthiobenzothiophen
• 英文别名: 5-Methylsulfanyl-1-benzothiophene
• CAS: 51846-60-7
• 化学式: C₉H₈S₂
• 分子量: 180.295
• InChiKey: PMZJSVBYQJFOQA-UHFFFAOYSA-N

物化性质

• 沸点：
  305.2±15.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-Methanesulfinyl-4-thiophen-2-yl-butan-2-one 以14%的产率得到
  参考文献：
  名称：

  OIKAWA I.; YONEMITSU O., J. ORG. CHEM. , 1976, 41, NO 7, 1118-1124

  摘要：

  DOI：

文献信息

• THIAZOLODERIATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Knoll GmbH

  公开号：EP1178993A1

  公开（公告）日：2002-02-13
• SUBSTITUTED IMIDAZOTHIAZOLES AS ANTIDEPRESSANT AGENTS
  申请人：Knoll GmbH

  公开号：EP1187836A1

  公开（公告）日：2002-03-20
• [EN] SUBSTITUTED IMIDAZOTHIAZOLES AS ANTIDEPRESSANT AGENTS<br/>[FR] IMIDAZOTHIAZOLES SUBSTITUES UTILISES EN TANT QU'AGENTS ANTIDEPRESSIFS
  申请人：KNOLL AG

  公开号：WO2000071548A1

  公开（公告）日：2000-11-30

  Compounds of Formula (I) including pharmaceutically acceptable salts thereof, in which A is S or O; R1 is H, halo, a C1-3 alkyl group or a C1-3 alkylthio group; R2 is H or fluoro; and R3 is methyl, ethyl or isopropyl are useful in the treatment of depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress and in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage.
• [EN] THIAZOLODERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE THIAZOLE ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES DERIVES
  申请人：KNOLL AG

  公开号：WO2000071549A1

  公开（公告）日：2000-11-30

  Compounds of formula (I); processes to prepare such compounds; compositions containing such compounds and their use in the treatment of depression, anxiety, psychoses (for examples schizophrenia), tardive dyskinesia, obesity, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, cerebral ischaemia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, stress, and their use in the treatment and/or prophylaxis of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, cerebral ischaemia, head injuries and haemorrhage and as an aid to smoking cessation; are described.